Vyvgart Crosses the Antibody Line in Seronegative Myasthenia Gravis

from TheBrief.Health · host TheBrief.Health

Phase 3 ADAPT SERON data show efgartigimod improves function in seronegative generalized myasthenia gravis, with FDA priority review potentially expanding targeted treatment options for underserved patients.

Episode metadata supplied by the publisher feed · Published Apr 27, 2026

Embed this episode

Attribution link and audio player

NOW PLAYING

Vyvgart Crosses the Antibody Line in Seronegative Myasthenia Gravis

0:00 2:02

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of TheBrief.Health?

This episode is 2 minutes long.

When was this TheBrief.Health episode published?

This episode was published on April 27, 2026.

Can I download this TheBrief.Health episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!